rich 1.0 Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, recaps 3 Hot Line trials from the European Society of Cardiology (ESC) Congress 2026 and their implications for pharmacists. CARDIO-TTRansform tested eplontersen (Wainua) in transthyretin amyloid cardiomyopathy and missed its primary endpoint (rate ratio, 0.89), though a pre-specified subgroup not on background TTR stabilizers showed nominal benefit—a reminder that lowering a biomarker does not guarantee clinical efficacy and that background therapy shapes trial results. SINGLE-AF found that direct oral anticoagulation reduced the primary composite endpoint by 69% in patients with atrial fibrillation at intermediate stroke risk, without increasing major bleeding, though absolute event rates were low. POET II showed that a response-tailored, shorter antibiotic course was non-inferior for selected patients with left-sided infective endocarditis, cutting median therapy from 41 to 26 days. The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest https://audioboom.com/channels/5151242-the-tell-tale-heart-the-pharmacist-s-cardiovascular-digest Audioboom https://audioboom.com 480 95 https://audioboom.com/i/43813236/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8946475/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>